Lymphoma Clinical Trials
1) 2ND line or greater/ SGN35-031: A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2) CTMX-M-2029-001 (CytomX) A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas.
3) MOR208C310 frontMIND: A Phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate, and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
4)NDS-DLBCL-003 Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study: The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, patient-level data longitudinally in patients diagnosed with various subtypes of NHL. The study will consist of 4 cohorts, as described in detail below: 1) patients with first R/R DLBCL who have initiated second-line (2L) systemic treatment; 2) patients with second R/R DLBCL who have initiated third line (3L) systemic treatment; 3) patients with first R/R FL who have initiated 2L systemic treatment; and 4) patients with first R/R PMBCL who have initiated 2L systemic treatment.
FOLLICULAR LYMPHOMA Grade 1 to 3a or R/R Marginal Zone Lymphoma (2)
1) INCMOR 0208-301 inMIND: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma.
2) NDS-DLBCL-003 Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study: The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, patient-level data longitudinally in patients diagnosed with various subtypes of NHL. The study will consist of 4 cohorts, as described in detail below: 1) patients with first R/R DLBCL who have initiated second-line (2L) systemic treatment; 2) patients with second R/R DLBCL who have initiated third line (3L) systemic treatment; 3) patients with first R/R FL who have initiated 2L systemic treatment; and 4) patients with first R/R PMBCL who have initiated 2L systemic treatment.
Send UsA Message
The Importance of Subspecialization in Oncology: Our Commitment at Charleston Oncology
The Importance of Subspecialization in Oncology: Our Commitment at Charleston OncologyAt Charleston Oncology, we know that a cancer diagnosis can be overwhelming. For most patients, the search for the right doctor quickly becomes one of the most important steps on...
Lung Cancer in Non-Smokers: What You Should Know
Lung Cancer in Non-Smokers: What You Should KnowAt Charleston Oncology, we understand that lung cancer is often linked to smoking, but it’s important to remember that lung cancer can affect anyone, even those who have never smoked. As part of Lung Cancer Awareness...
Why Early Detection Matters: Breast Cancer Screening Guidelines By Age
Why Early Detection Matters: Breast Cancer Screening Guidelines By AgeBreast cancer is the most common cancer diagnosed in women, but it is also one of the most treatable when found early. Early detection is the single most powerful tool we have in the fight against...
Proactive Health: Prostate and Blood Cancer Awareness
Proactive Health: Prostate and Blood Cancer AwarenessTaking charge of your health means being informed and proactive, especially when it comes to cancer prevention and early detection. This September, as we observe both Prostate Cancer Awareness Month and Blood Cancer...
The Patients’ Unique Needs
From diagnosis to treatment and follow-ups, Charleston Oncology, as a part of the Department of Bon Secours St. Francis’ leading multidisciplinary cancer care team, plays a vital role in guiding patients through their breast cancer journey.
Landing on Your Feet: Celebrating Life After Cancer
From diagnosis to treatment and follow-ups, Charleston Oncology, as a part of the Department of Bon Secours St. Francis’ leading multidisciplinary cancer care team, plays a vital role in guiding patients through their breast cancer journey.
